Unichem Labs

Mumbai, India Founded: 1944 • Age: 82 yrs Listed
Branded formulations, APIs, and biosimilars are manufactured.
Request Access
Report Incorrect Data
Page last updated

About Unichem Labs

Unichem Labs is a publicly listed company based in Mumbai (India) founded in 1944. Branded formulations, APIs, and biosimilars are manufactured. The company has 3,330 employees. Its chief executive, as recorded, is Prakash A Mody. Its Indian entity Unichem Laboratories Limited reported revenue of ₹2,540 Cr. Unichem Labs offers products and services including Formulations and Active Pharmaceutical Ingredients. Its focus areas include Traditional Pharmaceuticals and Diversified.

Company details

Unichem Labs was founded in 1944 in Mumbai, India, within the pharmaceutical sector. Active pharmaceutical ingredients and formulations are produced, with emphasis placed on gastroenterology, cardiology, diabetology, psychiatry, neurology, antibacterials, anti-infectives, and pain management. A biotech facility has been established for the development and commercialization of biosimilar products through recombinant DNA technologies. Operations are centered in India, serving global markets.

  • Headquarters Mumbai, India
  • Employees 3,330
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website unichemlabs.com
  • Social LinkedIn Facebook
  • Legal Name Unichem Laboratories Limited
Operational Areas
Healthcare → Traditional Health & Nutrition
Key Metrics
  • Market Cap
    ₹3,559 Cr

    UNICHEMLAB · NSE

  • Share Price
    ₹493.30

    -2.40% today

  • Revenue
    ₹2,202 Cr

    FY 2025-26 · +4.3% YoY

  • EBITDA
    ₹111 Cr

    Margin 5.0%

  • Net Profit
    ₹81.89 Cr

    FY 2025-26 · -40.1% YoY

  • P/E (TTM)
    29.0x

    P/B 1.3x

  • ROE
    3.2%

    ROCE 4.1%

  • Debt / Equity
    0.19

    Interest cover -216.2x

  • Latest Funding Round
    $126.03M (USD), Post-IPO

    Apr 2023

  • Investors
    Ipca Laboratories
  • Employee Count
    3,330

Products & Services of Unichem Labs

Unichem Labs offers a comprehensive portfolio of products and services, including Formulations and Active Pharmaceutical Ingredients.

Formulations
Pharmaceutical Products

Formulations are manufactured by Unichem Laboratories for various markets, contributing to health solutions.

Active Pharmaceutical Ingredients
Chemical Manufacturing

Active Pharmaceutical Ingredients are produced by Unichem Laboratories for integration into drug formulations, enhancing quality and sustainability.

Funding Insights of Unichem Labs

  • Total Rounds 1
  • Last Round Post-IPO — $126.03M
  • First Round $126.03M

    (Apr 2023)

  • Investors Count 1

All 1 funding rounds of Unichem Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Apr 2023$126.03MPost-IPO––
Ipca Laboratories
Valuation history

1 investors in total: 1 institutional.

Investors in Unichem Labs

Unichem Labs has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ipca Laboratories.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Ipca Laboratories
APIs and drug formulations are manufactured for therapeutic segments.
1949ipca.comMumbai, India
Premium access

Investor details for Unichem Labs

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Unichem Laboratories Limited (Unichem Labs)

Unichem Laboratories Limited is the primary company behind Unichem Labs. The board of Unichem Laboratories Limited currently have 6 directors; the longest-serving is Prakash Amrut Mody, appointed in 2008. 16 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Prakash Amrut Mody
DIN 00001285
Director01 Jul 200818 yrs 4 moUnichem Laboratories Limited
Pranay Premchand Godha
DIN 00016525
Director10 Aug 20233 yrs 2 moUnichem Laboratories Limited
Pabitrakumar Kalipada Bhattacharyya
DIN 07131152
Managing Director10 Aug 20233 yrs 2 moUnichem Laboratories Limited
Arun Lalchand Todarwal
DIN 00020916
Director05 Feb 20242 yrs 9 moUnichem Laboratories Limited
Anand Trimbak Kusre
DIN 00818477
Director05 Feb 20242 yrs 9 moUnichem Laboratories Limited
Swati Arvind Patankar
DIN 06594600
Additional Director05 Feb 20268 moUnichem Laboratories Limited

People of Unichem Labs

70 people are tracked at Unichem Labs (15 in leadership, 5 in board & advisors, 50 in team); the tracked headcount is 3,330.

NameRoleGroup
Prakash A Mody
Co-CEO & OwnerLeadership
Ganesh Patil
Senior General Manager Clinical ResearchLeadership
Pirthi Singh Chandel
Head-human ResourcesLeadership
Sanjay Nanotkar
General Manager ( Technology Transfer / Production And Process Research )Leadership
Bhaumik Joshi
Head Of Information Technology Department (cio/cto) - Leading IT For The Digital EraLeadership
Vaibhav Joshi
Plant Head & Compliance OfficerLeadership
Sandip R. Lawande
General Manager - EngineeringLeadership
Suresh Dodwad
General Manager Finance & AccountsLeadership
Runa Divkar
Human Resources Business PartnerLeadership
Shailesh Gupta
Head EHSLeadership
Dhananjay Sathe
Chief Scientific & Compliance OfficerLeadership
Anand Gulawani
Assistant General ManagerLeadership
Manoj Sharma
Head Of QualityLeadership
Vinay Londhe
Head Analytical DevelopmentLeadership
Ramesh Kumar
HR Business PartnerLeadership
Priti Puri
Independent DirectorBoard & advisors
Prafull Anubhai
Independent DirectorBoard & advisors
Prafull Sheth
Independent DirectorBoard & advisors
Anand Mahajan
Independent DirectorBoard & advisors
Pranay Premchand Godha
DirectorBoard & advisors

50 more people are available in the full profile.

Premium access

Complete people profiles for Unichem Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Unichem Labs

Unichem Labs is a publicly listed company on the NSE with ticker symbol UNICHEMLAB in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Feb 2001
  • Listed onNSE: UNICHEMLAB
  • Listed entityUnichem Laboratories Limited
  • Exchange sectorHealth technology
  • ISININE351A01035
  • Share price₹524.45 (-0.36% on the day) · 2026-10-14
  • Market capitalisation₹3,700 Cr
  • Price to earnings12.1
  • EPS (diluted, trailing year)₹43.22
  • Volume (last session)11,747

Financials of Unichem Labs

Exchange-reported figures of Unichem Laboratories Limited, the listed company behind Unichem Labs (NSE: UNICHEMLAB).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,202 Cr
+4.3% YoY
EBITDA
₹111 Cr
-58.3% YoY
Profit After Tax
₹81.89 Cr
-40.1% YoY
Net Worth
₹2,717 Cr
+10.9% YoY
Total Assets
₹3,247 Cr
+10.0% YoY
Total Debt
₹500 Cr
+8.8% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2022,1111,7851,3431,2701,2351,104
Revenue growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
EBITDA111265(38.74)(84.12)71.7290.77(50.82)
EBITDA margin+5.0%+12.6%-2.2%-6.3%+5.7%+7.4%-4.6%
Profit before tax292155(84.96)(176)21.9551.48(48.21)
Net profit81.89137(43.58)(178)31.5326.81(86.06)
Net profit margin+3.7%+6.5%-2.4%-13.3%+2.5%+2.2%-7.8%
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
Balance sheet
Total assets3,2472,9512,7222,7923,0122,7112,766
Net worth2,7172,4512,4382,4352,6182,5572,531
Total debt500460248314349119206
Cash & bank29511815818511482.45234
Net working capital1,7461,4111,1901,1861,078740889
Cash flow
Cash from operations3.64(7.02)14.00(85.09)(260)32.9819.82
Cash from investing194(242)63.31241100(65.97)(35.91)
Cash from financing1.86184(106)(81.30)191(121)(62.30)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue640633575521579527587533
Revenue growth (YoY)+10.6%+20.1%-2.1%-2.2%+14.1%+9.0%--
Other income15.3715.6123.4728720.976.829.2513.62
EBITDA50.2069.9435.3244.787.9222.4983.7085.52
EBITDA margin+7.8%+11.1%+6.1%+8.6%+1.4%+4.3%+14.3%+16.0%
Depreciation30.4929.9430.6131.2531.4731.7929.6930.54
Interest7.716.629.397.428.246.545.466.75
Profit before tax27.3748.9918.79293(10.82)(9.02)57.8061.85
Tax5.157.527.8829.141.071.454.834.00
Net profit22.2241.4710.91264(11.89)(10.47)52.9757.85
EPS (₹)3.165.891.5537.47(1.69)(1.49)7.508.19
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue1,4121,7361,4421,0729431,124904
Revenue growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
EBITDA(23.30)254(74.71)(206)(43.55)95.48(90.61)
EBITDA margin-1.7%+14.6%-5.2%-19.2%-4.6%+8.5%-10.0%
Profit before tax209183(92.18)(279)(86.74)65.66(63.81)
Net profit(15.57)159(36.24)(197)(55.17)54.08(54.86)
Net profit margin-1.1%+9.1%-2.5%-18.3%-5.9%+4.8%-6.1%
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
Balance sheet
Total assets2,7202,6212,4022,5362,8492,7342,692
Net worth2,6272,4602,2952,3842,6722,6972,647
Total debt64.0812370.301081321.4816.71
Cash & bank25888.6312915799.0357.59205
Net working capital1,2341,098943941837698753
Cash flow
Cash from operations52.6072.29(41.57)(117)(158)(32.61)(41.84)
Cash from investing210(176)59.61241104(72.79)(35.59)
Cash from financing(70.66)38.26(48.06)(61.76)95.80(45.07)(21.02)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue366356315357384461448437
Revenue growth (YoY)-4.7%-22.8%-29.7%-18.3%-1.4%---
Other income16.7222.2229121.404.2510.0518.937.08
Total expenses346356314382359386374372
EBITDA20.640.131.39(25.44)25.7474.9874.2164.50
EBITDA margin+5.6%+0.0%+0.4%-7.1%+6.7%+16.3%+16.6%+14.8%
Depreciation28.6928.9730.0230.1129.9327.4728.4526.39
Interest1.294.092.103.681.931.532.891.82
Profit before tax7.38(10.71)260(37.83)(1.87)56.0361.8043.37
Tax1.854.6843.712.10(0.02)4.8114.910.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue640633575521579527587533
Revenue growth (YoY)+10.6%+20.1%-2.1%-2.2%+14.1%+9.0%--
Other income15.3715.6123.4728720.976.829.2513.62
EBITDA50.2069.9435.3244.787.9222.4983.7085.52
EBITDA margin+7.8%+11.1%+6.1%+8.6%+1.4%+4.3%+14.3%+16.0%
Depreciation30.4929.9430.6131.2531.4731.7929.6930.54
Interest7.716.629.397.428.246.545.466.75
Profit before tax27.3748.9918.79293(10.82)(9.02)57.8061.85
Tax5.157.527.8829.141.071.454.834.00
Net profit22.2241.4710.91264(11.89)(10.47)52.9757.85
EPS (₹)3.165.891.5537.47(1.69)(1.49)7.508.19
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2022,1111,7851,3431,2701,2351,104
Revenue growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
Other income33935.3299.6038.5247.5150.1992.13
Total expenses2,0911,8461,8241,4271,1981,1441,155
Employee cost397402403356330307273
EBITDA111265(38.74)(84.12)71.7290.77(50.82)
EBITDA margin+5.0%+12.6%-2.2%-6.3%+5.7%+7.4%-4.6%
Depreciation12512512311391.1784.3681.67
Interest31.5921.0322.6617.316.115.127.85
Profit before tax292155(84.96)(176)21.9551.48(48.21)
Tax39.5417.078.8025.86(11.09)17.1511.97
Net profit81.89137(43.58)(178)31.5326.81(86.06)
Net profit margin+3.7%+6.5%-2.4%-13.3%+2.5%+2.2%-7.8%
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.0814.0814.0814.0814.0814.0814.08
Reserves & surplus2,7032,4372,4242,4212,6042,5432,517
Shareholders' funds (net worth)2,7172,4512,4382,4352,6182,5572,531
Minority interest0.000.000.000.000.000.000.00
Secured loans469430219297330101184
Unsecured loans31.3729.8028.3716.6518.7918.4722.47
Total debt500460248314349119206
Total liabilities3,2472,9512,7222,7923,0122,7112,766
Assets
Gross block1,9851,9941,9201,7501,3801,1811,102
Net block1,2131,3001,2521,257990884870
Capital work in progress10030.67123147494568330
Investments0.020.021.361.70264392550
Inventories975989736625600538397
Sundry debtors829779642589495250390
Cash & bank balances29511815818511482.45234
Loans & advances99.09144205188175270247
Total current assets2,1972,0291,7421,5871,3851,1411,267
Total current liabilities451618552401307401379
Net working capital1,7461,4111,1901,1861,078740889
Total assets3,2472,9512,7222,7923,0122,7112,766
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash89.5815518410977.46232310
Net cash from operating activities3.64(7.02)14.00(85.09)(260)32.9819.82
Net cash from investing activities194(242)63.31241100(65.97)(35.91)
Net cash from financing activities1.86184(106)(81.30)191(121)(62.30)
Net change in cash200(65.17)(29.00)74.5631.74(154)(78.40)
Closing cash29511815818511482.45234
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.3%+18.3%+32.9%+5.8%+2.8%+11.9%-
EBITDA growth-58.3%+783.7%+54.0%-217.3%-21.0%+278.6%-
PBT growth+89.1%+9998.0%+51.8%--57.4%+9998.0%+17.1%
Net income growth-40.1%+413.6%+75.5%-665.2%+17.6%+131.2%-
Revenue CAGR (3Y)+17.9%+18.5%+13.1%+6.8%+2.5%+14.9%+16.5%
EBITDA CAGR (3Y)-+54.6%-+18.3%--+7.1%
Profitability & leverage
Net income margin+11.5%+6.5%-5.3%-15.1%+2.6%+2.8%-5.5%
Return on capital employed+4.1%+6.2%-0.2%-4.5%+0.9%+1.7%-2.4%
Return on net worth+3.2%+5.6%-1.8%-7.1%+1.2%+1.1%-3.3%
Debt / equity0.190.140.120.130.090.060.08
Long-term debt / equity0.030.030.030.040.020.010.00
Interest cover-216.2214.99-14.00-8.76-31.4179.88-5.92
Efficiency & per share
Fixed asset turnover1.111.080.970.861.001.081.06
Inventory turnover2.242.452.622.192.232.643.00
Debtors turnover2.742.972.902.483.413.862.67
EPS (₹)35.9119.53(13.32)(28.72)4.704.88(8.55)
Dividend per share (₹)0.000.000.004.004.004.004.00
Book value per share (₹)386.00348.10346.35345.89371.90363.16359.54
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue366356315357384461448437
Revenue growth (YoY)-4.7%-22.8%-29.7%-18.3%-1.4%---
Other income16.7222.2229121.404.2510.0518.937.08
Total expenses346356314382359386374372
EBITDA20.640.131.39(25.44)25.7474.9874.2164.50
EBITDA margin+5.6%+0.0%+0.4%-7.1%+6.7%+16.3%+16.6%+14.8%
Depreciation28.6928.9730.0230.1129.9327.4728.4526.39
Interest1.294.092.103.681.931.532.891.82
Profit before tax7.38(10.71)260(37.83)(1.87)56.0361.8043.37
Tax1.854.6843.712.10(0.02)4.8114.910.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue1,4121,7361,4421,0729431,124904
Revenue growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
Other income36444.8398.4041.8542.0747.3799.17
Total expenses1,4361,4821,5171,2789861,028995
Employee cost277288283271251234205
EBITDA(23.30)254(74.71)(206)(43.55)95.48(90.61)
EBITDA margin-1.7%+14.6%-5.2%-19.2%-4.6%+8.5%-10.0%
Depreciation11910810510683.1975.8971.09
Interest11.807.6210.429.382.071.301.28
Profit before tax209183(92.18)(279)(86.74)65.66(63.81)
Tax50.4719.720.0020.61(31.32)11.56(7.50)
Net profit(15.57)159(36.24)(197)(55.17)54.08(54.86)
Net profit margin-1.1%+9.1%-2.5%-18.3%-5.9%+4.8%-6.1%
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital14.0814.0814.0814.0814.0814.0814.08
Reserves & surplus2,6132,4462,2812,3702,6582,6832,633
Shareholders' funds (net worth)2,6272,4602,2952,3842,6722,6972,647
Secured loans53.3411163.881021000.0015.21
Unsecured loans10.7411.656.426.5831.651.481.50
Total debt64.0812370.301081321.4816.71
Total liabilities2,7202,6212,4022,5362,8492,7342,692
Assets
Gross block1,9491,9261,7181,6911,3191,1281,039
Net block1,1891,2751,1651,236963850829
Capital work in progress10031.03122148494568331
Investments47.4945.6244.0840.51390520668
Inventories592584501480461386316
Sundry debtors583748558472381360323
Cash & bank balances25888.6312915799.0357.59205
Loans & advances100146195182170265242
Total current assets1,5341,5661,3831,2911,1101,0691,086
Total current liabilities300468440351273371333
Net working capital1,2341,098943941837698753
Total assets2,7202,6212,4022,5362,8492,7342,692
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash60.5812615694.1352.60203302
Net cash from operating activities52.6072.29(41.57)(117)(158)(32.61)(41.84)
Net cash from investing activities210(176)59.61241104(72.79)(35.59)
Net cash from financing activities(70.66)38.26(48.06)(61.76)95.80(45.07)(21.02)
Net change in cash192(65.07)(30.02)61.5441.53(150)(98.45)
Closing cash25888.6312915799.0357.59205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-18.6%+20.4%+34.5%+13.7%-16.1%+24.3%-
EBITDA growth-109.2%+439.8%+63.7%-372.0%-145.6%+205.4%-
PBT growth+14.6%+9998.0%+67.0%-221.7%-+9998.0%-221.8%
Net income growth-109.8%+537.5%+81.6%-256.2%-202.0%+198.6%-
Revenue CAGR (3Y)+9.6%+22.6%+8.7%+5.8%-0.9%+19.1%+16.2%
EBITDA CAGR (3Y)-51.6%--+31.4%-10.5%-+16.0%
Profitability & leverage
Net income margin+11.3%+9.4%-6.4%-27.9%-5.9%+4.8%-6.2%
Return on capital employed-0.1%+7.6%-1.1%-5.9%-3.0%+2.5%-2.3%
Return on net worth-0.6%+6.9%-1.6%-7.8%-2.1%+2.0%-2.1%
Debt / equity0.040.040.040.050.020.000.00
Long-term debt / equity0.020.020.020.030.020.000.00
Interest cover-8.295.24-5.78-3.01-1.636.64-0.79
Efficiency & per share
Fixed asset turnover0.730.950.850.710.771.040.91
Inventory turnover2.403.202.942.282.233.203.07
Debtors turnover2.122.662.802.512.543.292.76
EPS (₹)22.5823.15(13.09)(42.57)(7.87)7.68(8.00)
Dividend per share (₹)0.000.000.004.004.004.004.00
Book value per share (₹)373.17349.40325.94338.65379.52383.11375.99

Timeline of Unichem Labs

3 dated milestones of Unichem Labs across 79 years, from founding to its latest funding, stage changes and deals.

  1. Founded Unichem Labs is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $126.0M.

Web traffic of Unichem Labs

The website of Unichem Labs (unichemlabs.com) receives about 4.6K visits a month and ranks #3,871,645 among all websites worldwide, #4,923 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    4.6K

    ▼ 12.3% vs previous month

  • Unique visitors
    2.2K

    per month

  • Global rank
    #3,871,645

    among all websites

  • Category rank
    #4,923

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Unichem Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Albert David India
albertdavidindia.com
100%
3.2K#6,337,167View details
USV India
usvindia.com
95%
11.4K#2,386,041View details
Zeon lifesciences
zeonlifesciences.com
95%
13.7K#4,142,013View details
Cadila Pharmaceuticals Limited
cadilapharma.com
90%
18.5K#1,452,788View details
Fourrts Laboratories
fourrts.com
86%
13.9K#2,054,904View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 19 similar websites and full traffic analytics for Unichem Labs

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 19 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Unichem Labs (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Inventia Healthcare
Oral solid drug delivery systems are manufactured and developed.
1985Mumbai, Maharashtra, IndiaUSD 42.49 MUSD 89.42 M962
Strides Pharma Science
Generic, semi-solid, and liquid dosage forms are manufactured.
1990Bengaluru, Karnataka, IndiaUSD 508.93 M4,050
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
1983Mumbai, Maharashtra, IndiaUSD 6.44 B19,801
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Unichem Labs

UNICHEMLAB: Q2 CONS NET PROFIT 222M RUPEES VS LOSS 119M (YOY)
Exchange Update • 1 day ago
UNICHEMLAB: Q2 EBITDA 744M RUPEES VS 661M (YOY); Q2 EBITDA MARGIN 11.63% VS 11.43% (YOY)
Exchange Update • 1 day ago
Unichem Laboratories: USFDA inspection at Goa formulation facility concludes with 5 observations related to procedural enhancements; co to respond within 15 days.
Exchange Update • 1 month ago
Unichem Laboratories receives ₹94 crore GST order over penalty, interest - CNBC TV18
CNBCTV18 • 1 month ago
Unichem Laboratories: Company Hit with ₹87.07 Crore CGST Penalty, Aims to Appeal Decision.
Exchange Update • 1 month ago
Unichem Laboratories June-Quarter Consol PAT 414.7 Million Rupees
Reuters • 2 months ago
Aastha Spintex Ltd leads losers in 'B' group | Capital Market News - Business Standard
Business Standard • 3 months ago
Polunin Capital Partners picks up nearly 1% stake in Unichem Labs; Fidelity buys additional shares in Sunteck Realty
Moneycontrol • 3 months ago
Unichem Laboratories March-Quarter Consol Profit 109.1 Million Rupees
Reuters • 5 months ago
Unichem Laboratories Q4 net profit falls 79% on exceptional items - CNBC TV18
CNBCTV18 • 5 months ago
Premium access

Complete news archive for Unichem Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Unichem Labs

Unichem Labs was founded in 1944 and raised its 1st funding round 79 years after it was founded.

Unichem Labs is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.

Prakash A Mody is the CEO of Unichem Labs, as recorded in our data.

Unichem Labs has 3,330 employees.

The primary company behind Unichem Labs, Unichem Laboratories Limited, reported revenue of ₹2,540 Cr for FY 2026, up 4% year on year.

Unichem Labs was founded in 1944 in Mumbai, India, within the pharmaceutical sector. Active pharmaceutical ingredients and formulations are produced, with emphasis placed on gastroenterology, cardiology, diabetology, psychiatry, neurology, antibacterials, anti-infectives, and pain management. A biotech facility has been established for the development and commercialization of biosimilar products through recombinant DNA technologies. Operations are centered in India, serving global markets.

Unichem Labs offers Formulations and Active Pharmaceutical Ingredients.

Yes, Unichem Labs is publicly traded on NSE under the ticker symbol UNICHEMLAB.

Unichem Labs has 1 investor. Key investors include Ipca Laboratories.

Unichem Labs operates through Unichem Laboratories Limited.

The legal entities of Unichem Labs currently have 8 directors, including Prakash Amrut Mody, Swati Arvind Patankar, Sanjay Bhawarlal Jain and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available